- $271.70bn
- $332.38bn
- $400.28bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 12.51 | ||
| PEG Ratio (f) | 3.35 | ||
| EPS Growth (f) | 3.88% | ||
| Dividend Yield (f) | 3% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.86 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | 11.07 | ||
| Price to Sales | 0.66 | ||
| EV to EBITDA | 9.13 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 10.41% | ||
| Return on Equity | 24.33% | ||
| Operating Margin | 7.86% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 257,141 | 287,597 | 324,162 | 371,622 | 400,278 | 449,503.4 | 478,168.23 | 10.57% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +11.88 | +12.81 | +17.14 | +12.66 | +0.99 | -8.31 | +15.86 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
UnitedHealth Group Incorporated is a healthcare company. The Company operates two businesses, Optum and UnitedHealthcare. Optum serves the healthcare marketplace, including patients and consumers, payers, care providers, employers, governments and life sciences companies, through its Optum Health, Optum Insight and Optum Rx businesses. UnitedHealthcare offers a full range of health benefits, simplifying the healthcare experience and providing affordable solutions. The Company’s segments include Optum Health, Optum Insight, Optum Rx and UnitedHealthcare. The UnitedHealthcare segment includes UnitedHealthcare Employer & Individual, which serves consumers and employers; UnitedHealthcare Medicare & Retirement delivers health and well-being benefits to seniors and other Medicare-eligible consumers; and UnitedHealthcare Community & State serves consumers who are economically disadvantaged, the medically underserved and those without the benefit of employer sponsored health benefits coverage.
Directors
- Stephen Hemsley NEC (68)
- Dirk Mcmahon PRE (61)
- Andrew Witty CEO (56)
- John Rex CFO (59)
- Patricia Lewis CHO (58)
- Thomas Roos SVP (48)
- Michele Hooper LED (69)
- Richard Burke IND (77)
- Timothy Flynn IND (64)
- Paul Garcia IND (69)
- F. William McNabb IND (64)
- Valerie Montgomery Rice IND (59)
- John Noseworthy IND (70)
- Gail Wilensky IND (77)
- Last Annual
- December 31st, 2024
- Last Interim
- March 31st, 2025
- Incorporated
- July 1st, 2015
- Public Since
- October 17th, 1984
- No. of Shareholders
- 9,323
- No. of Employees
- 400,000
- Sector
- Healthcare Providers & Services
- Industry
- Healthcare
- Exchange
New York Stock Exchange- Shares in Issue
- 907,140,441
- Address
- 1 HEALTH DRIVE, EDEN PRAIRIE, 55344
- Web
- https://www.unitedhealthgroup.com/
- Phone
- +1 9529361300
- Auditors
- Deloitte & Touche LLP
Latest News for UNH
Upcoming Events for UNH
Q2 2025 Unitedhealth Group Inc Earnings Release
Q2 2025 UnitedHealth Group Inc Earnings Call
Q3 2025 Unitedhealth Group Inc Earnings Release
Similar to UNH
Agilon Health
New York Stock Exchange
AMERICAN WELL
New York Stock Exchange
AMN Healthcare Services
New York Stock Exchange
Ardent Health
New York Stock Exchange
Auna SA
New York Stock Exchange
FAQ
As of Today at 05:52 UTC, shares in Unitedhealth are trading at $299.51. This share price information is delayed by 15 minutes.
Shares in Unitedhealth last closed at $299.51 and the price had moved by -40.21% over the past 365 days. In terms of relative price strength the Unitedhealth share price has underperformed the S&P500 Index by -46.83% over the past year.
The overall consensus recommendation for Unitedhealth is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreThe Unitedhealth dividend yield is 2.8% based on the trailing twelve month period.
Last year, Unitedhealth paid a total dividend of $8.40, and it currently has a trailing dividend yield of 2.8%. We do not have any data on when Unitedhealth is to next pay dividends.
We do not have data on when Unitedhealth is to next pay dividends. The historic dividend yield on Unitedhealth shares is currently 2.8%.
To buy shares in Unitedhealth you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $299.51, shares in Unitedhealth had a market capitalisation of $271.70bn.
Here are the trading details for Unitedhealth:
- Country of listing: United States
- Exchange: NYQ
- Ticker Symbol: UNH
Based on an overall assessment of its quality, value and momentum Unitedhealth is currently classified as a Contrarian. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Unitedhealth is $378.38. That is 26.33% above the last closing price of $299.51.
Analysts covering Unitedhealth currently have a consensus Earnings Per Share (EPS) forecast of $22.10 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Unitedhealth. Over the past six months, its share price has underperformed the S&P500 Index by -46.55%.
As of the last closing price of $299.51, shares in Unitedhealth were trading -38.2% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Unitedhealth PE ratio based on its reported earnings over the past 12 months is 12.51. The shares last closed at $299.51.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Unitedhealth's management team is headed by:
- Stephen Hemsley - NEC
- Dirk Mcmahon - PRE
- Andrew Witty - CEO
- John Rex - CFO
- Patricia Lewis - CHO
- Thomas Roos - SVP
- Michele Hooper - LED
- Richard Burke - IND
- Timothy Flynn - IND
- Paul Garcia - IND
- F. William McNabb - IND
- Valerie Montgomery Rice - IND
- John Noseworthy - IND
- Gail Wilensky - IND